Each guideline recommendation is based on the best available body of evidence obtained through systematic reviews and developed using the GRADE Evidence to Decision Framework.
The European Commission's Joint Research Centre (JRC) has launched a call for feedback from the public on draft recommendations addressing whether aspirin and non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs) should be used for the primary prevention of colorectal cancer. The comments collected through this open consultation will be analysed for potential consideration when defining the final recommendations.
Draft Evidence to Decision Framework - Aspirin for CRC primary prevention
Draft Evidence to Decision Framework - non-aspirin NSAIDs for CRC primary prevention
How to comment
This website is publicly accessible. Any visitor can comment on any of the listed documents. However, readers should note that these documents have been written using medical and scientific language and are defined based on the methodological framework for quality assurance development, including reviews of existing literature on the topic.
The comments provided should be substantiated by evidence stating the rationale and/or supporting publications or other public documentation. In the case a reference is provided for consideration by the working group, it must state the name of authors, journal, and date of publication.
Please note contributions will not be considered if they:
are submitted after the deadline of the feedback call,
are not submitted via the platform provided,
are not related to the contents of the document,
contain complaints against institutions, personal accusations, irrelevant or offensive statements or material, and/or
are related to policy aspects outside the scope of the EC Initiatives on Cancer Screening and Care's activities.
You will receive acknowledgement from the system that your comments have been successfully transmitted. The JRC will accordingly assess all comments submitted in line with the aforementioned criteria.
Please note that the JRC will not provide individual responses. The assessed comments will be further evaluated by the working group and systematic review team for consideration when defining the final outputs, following the methodological framework for guideline and quality assurance development.
